logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Michiel S. van der Heijden

netherlands cancer institute
H指数:53
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tremelimumab with or without durvalumab in combination with paclitaxel in metastatic urothelial cancer: phase I/II ICRA trial

曲美木单抗联合或不联合度伐利尤单抗，与紫杉醇联用治疗转移性尿路上皮癌：ICRA I/II期临床试验

Nature Communications
IF15.7
2026-06-170
OAAI
Sarah M. H. Einerhand; Hamza Ali; Stephen Q. Wong; Jeroen van Dorp; Tatum van Maanen; Jeantine M. de Feijter; Maurits L. van Montfoort; Thierry N. Boellaard; Linde M. Braaf; Wim Brugman; Daniel J. Vis; Cindy M. J. Hollander; Antonios Daletzakis; Helga A. Schrijver; Karen Snapper; Sjoukje F. Oosting; Cheryl P. Bruijnen; Lodewyk F. A. Wessels; Keith S. Chan; Britt B. M. Suelmann; Michiel S. van der Heijden
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial

伊匹单抗和nivolumab联合放化疗作为肌肉浸润性膀胱癌的保留膀胱治疗: 一项2期试验

Nature Medicine
IF50
2026-02-270
PRE
Jan-Jaap J. Mellema; Chantal F. Stockem; Cameron Herberts; Samantha K. Cheung; Daniel J. Vis; Bas W. G. van Rhijn; Laura S. Mertens; Thierry N. Boellaard; Maurits L. van Montfoort; Sara Balduzzi; Jeantine M. de Feijter; Johannes C. K. van der Mijn; Shruti Sharma; Adam C. El Naggar; Joost L. Boormans; Martine Franckena; Richard P. Meijer; Juus L. Noteboom; Eva E. Schaake; Debbie G. J. Robbrecht; Britt B. M. Suelmann; Michiel S. van der Heijden
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers

高级泌尿肿瘤共识会议（AUC3）2025：肾细胞癌和尿路肿瘤管理的专家共识

CA: A Cancer Journal for Clinicians
IF0
2025-12-130
OAAI
Rana R. McKay MD; Sumanta Pal MD; Wanling Xie MS; David Aggen MD, PhD; Laurence Albiges MD, PhD; Andrea Apolo MD; Michael B. Atkins MD; Rick Bangs MBA, PMP; Kathryn E. Beckermann MD, PhD; Joaquim Bellmunt MD, PhD; Stephanie A. Berg DO; Mehmet A. Bilen MD; David Braun MD, PhD; Maria I. Carlo MD; Jason Efstathiou MD, DPhil; Matthew Galsky MD; Petros Grivas MD, PhD; Shilpa Gupta MD; Naomi Haas MD; A. Ari Hakimi MD; Hans Hammers MD, PhD; Daniel Y. C. Heng MSC; Michelle Hirsch MD, PhD; Gopakumar Iyer MD; Eric Jonasch MD; Vadim S. Koshkin MD; Oleksandr Kryvenko MD; Bryan Lewis JD; Roger Li MD; Surena Matin MD; Benjamin Maughan MD, PharmD; David F. McDermott MD; Bradley McGregor MD; Joshua Meeks MD, PhD; Matthew Milowsky MD; Robert Motzer MD; Andrea Necchi MD; Dan Petrylak MD; Sima Porten MD, MPH; Thomas Powles MBBS, MRCP, MD; Brian Rini MD; Brian Shuch MD; Arlene Siefker-Radtke MD; Guru Sonpavde MD; S. Srikala Sridhar MD; Cristina Suarez MD, PhD; Chad Tang MD; Abhishek Tripathi MD; Michiel S. Van Der Heijden MD, PhD; Martin Voss MD; Wenxin Xu MD; Tian Zhang MD; Jonathan Rosenberg MD; Toni K. Choueiri MD
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: the NABUCCO trial

局部晚期尿路上皮癌术前伊匹木单抗和纳武利尤单抗的最终临床分析及肿瘤引流淋巴结组成的探索：NABUCCO试验

European Journal of Cancer
IF7.1
2025-08-210
PRE
Chantal F. Stockem; Jeroen van Dorp; Nick van Dijk; Daniel J. Vis; Rolf Harkes; Bram van den Broek; Maartje Alkemade; Annegien Broeks; Kees Hendricksen; Thierry N. Boellaard; Jeantine M. de Feijter; Maurits L. van Montfoort; Antonios Daletzakis; Antoine G. van der Heijden; Richard P. Meijer; Niven Mehra; Lodewyk F.A. Wessels; Bas W.G. van Rhijn; Britt B.M. Suelmann; Michiel S. van der Heijden
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma

EV-302研究的探索性亚组分析：一项评估恩诺单抗（enfortumab vedotin）联合帕博利珠单抗（pembrolizumab）与化疗对比治疗既往未治疗的局部晚期或转移性尿路上皮癌的III期全球研究

ESMO Open
IF8.3
2025-08-110
OAAI
M.S. van der Heijden; T. Powles; S. Gupta; Y. Loriot; M.D. Galsky; B.P. Valderrama; S.S. Sridhar; E.Y. Yu; G. Iyer; E. Kikuchi; D. Castellano; J. Hoffman-Censits; A. Drakaki; N. Mar; J.P. Maroto Rey; C. Vulsteke; W. Arafat; I. Duran; N.A. Dawson; U. Swami; S. Gorla; B.H. Moreno; X. Yu; Y.-T. Lu; J. Bedke
Health-related quality of life in patients treated for non-metastatic muscle-invasive bladder cancer: radical cystectomy versus bladder preserving therapy

非转移性肌层浸润性膀胱癌患者的治疗相关生活质量：根治性膀胱切除术与保留膀胱疗法的比较

international journal of radiation oncology biology physics
IF0
2025-07-030
OAAI
Katharina Brück; Vera Atema; Annemarie M. Leliveld; Martine Franckena; Richard P. Meijer; Michiel S. van der Heijden; A. Rogier Donders; J. Alfred Witjes; Carin A. Uyl-de Groot; Lisa M.C. van Hoogstraten; Lambertus A. Kiemeney; Joost L. Boormans; Katja K.H. Aben; Maarten C.C.M. Hulshof
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

表观遗传谱分析鉴定了内分泌抵抗的标志物及转移性去势抵抗性前列腺癌的治疗选择

Cell Reports Medicine
IF10.6
2025-07-020
OAAI
Tesa M. Severson; Emma Minnee; Yanyun Zhu; Karianne Schuurman; Holly M. Nguyen; Lisha G. Brown; Sini Hakkola; Renee Menezes; Sebastian Gregoricchio; Yongsoo Kim; Jeroen Kneppers; Simon Linder; Suzan Stelloo; Cor Lieftink; Michiel S. van der Heijden; Matti Nykter; Vincent van der Noort; Joyce Sanders; Ben Morris; Guido Jenster; Geert JLH van Leenders; Mark Pomerantz; Matthew L. Freedman; Roderick L. Beijersbergen; Alfonso Urbanucci; Lodewyk Wessels; Peter S. Nelson; Eva Corey; Stefan Prekovic; Wilbert Zwart; Andries M. Bergman
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial☆

恩诺单抗维多汀联合帕博利珠单抗治疗未经治疗的局部晚期或转移性尿路上皮癌：III期EV-302/KEYNOTE-A39试验的中位2.5年随访结果☆

Annals of Oncology
IF65.4
2025-06-010
PREAI
T.B. Powles; M.S. Van der Heijden; Y. Loriot; J. Bedke; B.P. Valderrama; G. Iyer; E. Kikuchi; J. Hoffman-Censits; C. Vulsteke; A. Drakaki; S. Rausch; W. Arafat; S.H. Park; U. Swami; J.-R. Li; I. Duran; S. Gorla; B. Homet Moreno; X. Yu; Y.-T. Lu; S. Gupta
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

恩诺单抗维多汀联合帕博利珠单抗对比化疗在先前未经治疗的局部晚期或转移性尿路上皮癌患者中的疗效（EV-302）：一项开放标签、随机对照、III期研究的患者报告结局

lancet oncology
IF0
2025-05-280
PRE
Shilpa Gupta; Yohann Loriot; Michiel S Van der Heijden; Jens Bedke; Begoña P Valderrama; Eiji Kikuchi; Aude Fléchon; Daniel Petrylak; Maria De Santis; Matthew D Galsky; Jae Lyun Lee; Umang Swami; Srikala S Sridhar; Ugo De Giorgi; Phoebe Wright; Vanessa Shih; Yi-Tsung Lu; Xuesong Guan; Ryan Dillon; Aditya Shetty; Blanca Homet Moreno; Jennifer L Beaumont; Intan Purnajo; Shauna McManus; Thomas Powles
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial

CheckMate 901试验中，仅淋巴结转移性尿路上皮癌患者接受纳武利尤单抗联合吉西他滨-顺铂治疗与单独吉西他滨-顺铂治疗的特征分析

European Urology
IF25.2
2025-05-200
OAAI
Matthew D. Galsky; Michiel S. van der Heijden; Thomas Powles; Melanie Claps; Mauricio Burotto; Michael Schenker; Juan Pablo Sade; Aristotelis Bamias; Philippe Beuzeboc; Jens Bedke; Jan Oldenburg; Yüksel Ürün; Dingwei Ye; Begoña P. Valderrama; Yoshihiko Tomita; Ruiyun Jiang; Jeiry Filian; Lily Wang; Maximiliano van Kooten Losio; Guru Sonpavde
Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39

恩夫妥木单抗联合帕博利珠单抗（EV联合P）对比化疗（Chemo）在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中的疗效：EV-302/KEYNOTE-A39的泛亚洲亚组分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Kikuchi, E.; van der Heijden, M. S.; Perez Valderrama, B.; Gupta, S.; Bedke, J.; Shin, S. J.; Li, J-R.; Guo, J.; Danchaivijitr, P.; Kanesvaran, R.; Park, S. H.; Su, W-P.; Kandori, S.; Bae, W. K.; Wong, A. S.; Lu, J.; Yu, X.; Shetty, A.; Bavle, A. A.; Powles, T. B.
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

阿特珠单抗单药治疗转移性尿路上皮癌: imvior210 II期临床试验的最终分析

ESMO OPEN
IF8.3
2024-12-010
PRE
Rosenberg, J. E.; Galsky, M. D.; Powles, T.; Petrylak, D. P.; Bellmunt, J.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Perez-Gracia, J. L.; van der Heijden, M. S.; Dreicer, R.; Duran, I.; Castellano, D.; Drakaki, A.; Retz, M.; Sridhar, S. S.; Grivas, P.; Yu, E. Y.; O'Donnell, H.; Burris, H. A.; Mariathasan, S.; Shi, Y.; Goluboff, E.; Bajorin, D.
Association of PD-L1 expression with clinical response to TAR-200 in the phase IIb SunRISe-1 trial

PD-L1表达与TAR-200临床反应的相关性：SunRISe-1期IIb临床试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Xylinas, E.; Pieczonka, C.; Jacob, J. M.; Necchi, A.; Daneshmand, S.; Simone, G.; Decaestecker, K.; Kulkarni, G.; Boegemann, M.; Guerrero-Ramos, F.; Callaway, J.; Beeharry, N.; Zhang, J.; Hampras, S.; Sweiti, H.; Stromberg, K.; Martin, J.; Shukla, A.; Raciti, P.; van der Heijden, M. S.
EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

EV-302：探索性分析nectin-4表达及对一线恩夫妥单抗 vedotin（EV）联合帕博利珠单抗（P）的应答，在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中

ANNALS OF ONCOLOGY
IF65.4
2024-09-015
PRE
Powles, T. B.; Van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Rey, J. P. Maroto; Vulsteke, C.; Iyer, G.; Swami, U.; Shin, S. J.; Rodriguez-Vida, A.; Wozniak, M.; Moreno, B. Homet; Lu, J.; Yu, C.; Hogdal, L.; Loriot, Y.

研究方向

暂未获取到该数据
T
Thomas Powles
H 指数:77论文数:690被引数:3.6万
Y
Yohann Loriot
H 指数:76论文数:1,129被引数:5.3万
B
Bas W.G. van Rhijn
H 指数:53论文数:388被引数:2.0万
A
Andrea Necchi
H 指数:70论文数:1,307被引数:3.2万
N
Nick van Dijk
H 指数:12论文数:50被引数:1,040
I
Ignacio Durán
H 指数:54论文数:346被引数:1.6万
D
Daniel Castellano
H 指数:72论文数:739被引数:4.0万
B
Begoña P. Valderrama
H 指数:25论文数:176被引数:6,584
D
Daniël J. Vis
H 指数:31论文数:116被引数:8,605
B
Bernadett Szabados
H 指数:24论文数:216被引数:3,600